Michael Ulz
Stock Analyst at Morgan Stanley
(4.78)
# 109
Out of 5,139 analysts
100
Total ratings
67.24%
Success rate
37.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $48 → $81 | $63.84 | +26.88% | 7 | Jan 7, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $46 → $50 | $16.71 | +199.31% | 3 | Dec 9, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $81 → $95 | $91.05 | +4.34% | 5 | Dec 9, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.36 | +199.04% | 3 | Dec 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $76.33 | +23.15% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $33.92 | +200.71% | 4 | Oct 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $6.31 | +232.81% | 8 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $405 → $475 | $359.27 | +32.21% | 12 | Oct 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $5.04 | +396.03% | 12 | May 9, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.20 | +900.00% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $15.37 | +88.68% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $2.36 | +747.46% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.91 | +423.56% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.19 | +488.24% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $12.12 | +122.77% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.03 | +1,841.75% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.64 | +1,136.26% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.64 | +1,462.26% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.56 | -34.21% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $6.06 | +395.05% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $22.49 | +255.71% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.33 | +4.68% | 3 | Jul 12, 2017 |
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Equal-Weight
Price Target: $48 → $81
Current: $63.84
Upside: +26.88%
Dyne Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $46 → $50
Current: $16.71
Upside: +199.31%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Overweight
Price Target: $81 → $95
Current: $91.05
Upside: +4.34%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.36
Upside: +199.04%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $76.33
Upside: +23.15%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $33.92
Upside: +200.71%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $6.31
Upside: +232.81%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Equal-Weight
Price Target: $405 → $475
Current: $359.27
Upside: +32.21%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.04
Upside: +396.03%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.20
Upside: +900.00%
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $15.37
Upside: +88.68%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.36
Upside: +747.46%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.91
Upside: +423.56%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.19
Upside: +488.24%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $12.12
Upside: +122.77%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.03
Upside: +1,841.75%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.64
Upside: +1,136.26%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.64
Upside: +1,462.26%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.56
Upside: -34.21%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $6.06
Upside: +395.05%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $22.49
Upside: +255.71%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.33
Upside: +4.68%